IL2RA and graft versus host disease: Anti-CD25 monoclonal antibodies, which specifically target interleukin-2 receptor alpha (IL-2Rα), play a crucial role in inhibiting T lymphocyte activation and have demonstrated efficacy in mitigating GVHD (4–6).